anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject therapeutic agent containing an expression inhibitor for a perchloric acid-soluble protein as an active ingredient, capable of promoting the proliferation of uriniferous tubuliform cells and useful for treating renal diseases. SOLUTION: This therapeutic agent containing an expression inhibitor for a perchloric acid-soluble protein(PSP) as an active ingredient is obtained. The expression inhibitor for the PSP is capable of inhibiting the expression of the PSP in uriniferous tubuliform cells and is preferably a PSP derived from a human kidney or its derivative. The PSP is a protein extracted with perchloric acid and having 14 kDa molecular weight and can be extracted and purified from a biological tissue. A substance in which a part of the amino acid sequence of the PSP is deleted or substituted with other amino acids, etc., is cited as the PSP derivative. The therapeutic agent is used together with a filler, an extender, etc., and can be converted into a pharmaceutical preparation composition. The active ingredient is contained in an amount of preferably 1-70 wt.% in the pharmaceutical preparation.  The daily dose thereof administered is preferably 0.01 μg to 10 mg based on 1 kg body weight expressed in terms of the PSP.
The invention comprises an aqueous composition comprising riboflavin in a concentration higher than that obtainable in water alone and a non-toxic, water-soluble salt of a hydroxynaphthoic acid as solubilizer and its preparation by adding the corresponding hydroxy-naphthoic acid to an aqueous solution of riboflavin.  As solubilizer, any of the non-toxic water-soluble salts of the isomeric hydroxynaphthoic acids may be used but sodium 3-hydroxy-2-naphthoate is preferred.  Specification 450,145, [Group VI], is referred to.ALSO:The invention comprises an aqueous composition comprising riboflavin in a concentration higher than that obtainable in water alone and a non-toxic water soluble salt of a hydroxy naphthoic acid as solubilizer, e.g. the sodium, potassium, lithium, magnesium, ammonium and organically substituted ammonium salts. There may be also incorporated therein thiamine hydrochloride, nicotinamide, dpentothenyl choline chloride inositol and water in-C, pentothenic acid, folic acid, biotin, choline chloride, inositol and water insoluble vitamins such as vitamin A, vitamin D2, vitamin D3, a -tocopherol and/or other water-insoluble ingredients with a suitable dispersing agent. Specification 450,145 is referred to.
The recommended dosage of VYLEESI is 1.75 mg administered subcutaneously in the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. The duration of efficacy after each dose is unknown and the optimal window for VYLEESI administration has not been fully characterized. Patients may decide the optimal time for VYLEESI administration based on how they experience the duration of effect on desire and any adverse reactions such as nausea [see Warnings and Precautions (5.3)].

Patients should not administer more than one dose within 24 hours. The efficacy of consecutive doses within 24 hours has not been established and administering doses close together may increase the risk of additive effects on blood pressure [see Warnings and Precautions (5.1)].

Administering more than 8 doses per month is not recommended. Few patients in the phase 3 program received more than 8 doses per month. Also, more frequent dosing increases the risk for focal hyperpigmentation and the length of time per month when blood pressure is increased [see Warnings and Precautions (5.1, 5.2)].

VYLEESI is self-administered via a prefilled autoinjector pen. Visually inspect the drug product for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if the solution is cloudy, discolored, or visible particles are observed.
In Pakistan, the Learning through Play parenting program was tested initially through a cluster randomized study in a rural area of Pakistan. The results of this recently completed cluster RCT funded by the Grand Challenges Canada (GCC) showed that LTP Plus works and benefits both the mother and the child. More specifically, the results indicate a significant reduction in maternal depression.

Purpose of this cluster RCT is to determine if supported implementation of the LTP plus programme improves infant development compared to standard implementation of the LTP plus programme. This is an implementation trial comparing two ways of introducing LTP plus. A Cluster RCT of culturally adapted intervention LTP Plus will be conducted in the villages of Gadap town, Karachi, Pakistan. Total 60 villages will be randomized in two groups LTP plus and LTP plus supported implementation. Each cluster will be made of up to 15 mothers. Participants will be screened using eligibility checklist. Assessments will be done at baseline and after completion of intervention (3-month). All follow ups will be done by independent RAs, not involved in delivering intervention sessions.
PROBLEM TO BE SOLVED: To shorten a treating time while suppressing the generation of lump particles. SOLUTION: One or plural spray nozzles 8 for spraying a spray soln. in mist-like by spray air are provided in a treating chamber 4a. The spray nozzle 8, enables a high volume soln. injection of >=700 NL/min spray air flow rate and 360 g/min spray soln. flow rate per one spray nozzle. The treating time per one batch can be shortened compared with the conventional method while suppressing the generation of the lump particles by executing high concn. soln. injection and the high volume soln. injection by using the high volume spray nozzle 8.
This is a single-arm and open-label study to explore XVRd (ATG-010, Bortezomib, Lenalidomide and Dexamethasone) regimen in high-risk newly diagnosed multiple myeloma. Approximately 3-42 patients will be enrolled in the study. In dose escalation phase, patients with high-risk NDMM will be treated with VRd standard regimen (bortezomib 1.3mg/m2 SC on day1,4,8,11, lenalidomide 25 mg on day 1-14 and dexamethasone 40mg on day 1,8,15 in a 21-day cycle) plus escalating doses of selinexor 40 mg or 60 mg on days 1, 8, and 15 of each cycle in a 3+3 design. The primary objective of the dose escalation study is to determine the safety, tolerability,and recommended phase II dose (RP2D) of selinexor; Then dose expansion at the RP2D level based on dose escalation phase will be conducted to evaluate the efficacy, safety and tolerability. All of the patients will receive 12 cycles of XVRd , and subjects can choose maintenance treatment with XR after 12 cycles of XVRd.The primary objective of the dose escalation study is to determine the safety, tolerability, and recommended phase II dose (RP2D) of selinexor; Then dose expansion at the RP2D level based on dose escalation phase will be conducted to evaluate the efficacy, safety and tolerability.

The enrollment period for this study is expected to be approximately 12 months. The study will end when all patients have completed 12 cycles treatment/follow-up since the initiation of the study drug, or the last patient has expired, has been lost to follow-up, or has withdrawn consent, whichever occurs first.
Shark liver oil is vacuum distilled to give a residue which when hydrolysed by lipase of Ricinus seeds and further vacuum distilled yields a concentrate containing fatty acid esters of glycerol ethers. The latter may be saponified with KOH and the unsaponifiable fraction extracted with ether.  A product having a high (85% w/w) content of free glycerol ethers may be obtained from the fraction after removal of ether and vacuum steam-stripping of the residue.ALSO:An internally-administrable pharmaceutical preparation in dosage unit form comprises at least one glycerol ether of the formula CH2OH, CHOH, CH2OR wherein R is a C14-26 aliphatic hydrocarbon radical, or an ester thereof, together with a diluent or carrier.  Preferred glycerol ethers are those known as batyl, chimyl, and selachyl alcohols and glycerol a -monoaliphatic ethers wherein the radical R contains 16C atoms and one double bond.  The esters may be mono- or di-esters and are preferably derived from naturally occurring saturated or unsaturated fatty acids.  Such esters may be derived from various fish liver oils.  The preparations have a wide spectrum of physiological activity, including anti-infective properties, the ability to alleviate psychotic symptoms, and growth-stimulating activity, particularly of various kinds of blood cells.
The necessity of oxygen for metabolic processes means that hypoxia can lead to serious cell and tissue damage. On the other hand, in some situations, hypoxia occurs under physiological conditions and serves as an important regulation factor. The airway epithelium is specific in that it gains oxygen not only from the blood supply but also directly from the luminal air. Many respiratory diseases are associated with airway obstruction or excessive mucus production thus leading to luminal hypoxia. The main goal of this review is to point out how the airway epithelium reacts to hypoxic conditions. Cells detect low oxygen levels using molecular mechanisms involving hypoxia-inducible factors (HIFs). In addition, the cells of the airway epithelium appear to overexpress HIFs in hypoxic conditions. HIFs then regulate many aspects of epithelial cell functions. The effects of hypoxia include secretory cell stimulation and hyperplasia, epithelial barrier changes, and ciliogenesis impairment. All the changes can impair mucociliary clearance, exacerbate infection, and promote inflammation leading to damage of airway epithelium and subsequent airway wall remodeling. The modulation of hypoxia regulatory mechanisms may be one of the strategies for the treatment of obstructive respiratory diseases or diseases with mucus hyperproduction. Keywords: Secretory cells, Motile cilia, Epithelial barrier, Oxygenation, Obstructive respiratory diseases.
BACKGROUND: Overweight/obesity is a growing concern in schizophrenia (SZ). A few studies have shown that excessive oxidative stress and abnormal antioxidants were associated with pathogenesis and psychiatric symptoms in first episode antipsychotics naïve (FEAN) patients with SZ. However, there is no study has explored the interrelationships between total antioxidant status (TAS) and the severity of psychiatric symptoms in the early stage of SZ. This study aimed to evaluate the impact of overweight/obesity on psychiatric symptoms in FEAN patients with SZ.
METHODS: A total of 241 patients with FEAN SZ and 119 healthy controls were recruited and symptoms were evaluated by the Positive and Negative Syndrome Scale (PANSS). TAS levels were also measured in patients and healthy controls.
RESULTS: We found a significant negative association between body mass index (BMI) and TAS in FEAN patients, but not in controls. In addition, BMI and TAS were negatively associated with psychiatric symptoms. Interestingly, further regression analysis revealed that the interaction between BMI and TAS was associated with the negative symptoms in the early stage of SZ.
CONCLUSIONS: Our study indicates that abnormal TAS levels interacting with overweight/obesity may be involved in the pathophysiology of SZ, in particular negative symptoms.
NEW MATERIAL:The organic germanium compound of formula I . USE:Antimetabolic agent. The agent is supposed to have both of the pharmacological activity of the uracil fragment and that of the Ge-O bond. It has higher pharmacological characteristics than known organic germanium compounds. PROCESS:The uracil of formula II with acetylated with acetyl chloride, etc., and the resultant diacetyl derivative of formula III is made to react with trichlorogermane to obtain the trichlorogermyl derivative of formula IV. After separating the intermediate of formula V from the product, the intermediate is hydrolyzed to obtain the compound of formula I .
The determinants and driving forces of communication abilities in the locked-in state are poorly understood so far. Results from an experimental-clinical study on a completely paralyzed person involved in communication sessions after the implantation of a microelectrode array were retrospectively analyzed. The aim was to focus on the prerequisites and determinants for learning to control a brain-computer interface for communication in paralysis. A comparative examination of the communication results with the current literature was carried out in light of an ideomotor theory of thinking. We speculate that novel skill learning took place and that several aspects of the wording of sentences during the communication sessions reflect preserved cognitive and conscious processing. We also present some speculations on the operant learning procedure used for communication, which argues for the reformulation of the previously postulated hypothesis of the extinction of response planning and goal-directed ideas in the completely locked-in state. We highlight the importance of feedback and reinforcement in the thought-action-consequence associative chain necessary to maintain purposeful communication. Finally, we underline the necessity to consider the psychosocial context of patients and the duration of complete immobilization as determinants of the 'extinction of thinking' theory and to identify the actual barriers preventing communication in these patients.
The core intervention will utilize innovative wireless technology to provide patients with 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. The core intervention will be personalized by each intervention arm patient, who may choose features to suit their preferences.
PURPOSE: To obtain an abrasive dentifrice composition comprising a dicalcium phosphate and a metal ion-free peroxide compound, stable to active oxygen level and useful for whitening of tooth and removal of freckle. CONSTITUTION: This dentifrice composition comprises 20-60 wt.% dicalcium phosphate and 1-20 wt.% peroxide compound not containing a metallic ion (e.g. urea peroxide) and as necessary, further a chelating agent (e.g. phosphoric acid), a humectant (e.g. polyethylene glycol), a thickener (e.g. carboxymethyl cellulose), a surfactant, flavor ingredient, a synthetic anion linear polymer polycarboxylate, a dental calculus-preventing pyrophosphoric acid salt, an acting agent for reducing perception. The composition can strengthen tooth and rapidly whiten tooth. When the composition is applied to the surface of tooth, the tooth can be whitened and polished without giving injury to oral cavity tissue.
The invention discloses compound traditional Chinese medicine capable of promoting growing of broilers. The medicine includes the following raw materials by mass: 5-12 parts of astragalus membranaceus, 5-10 parts of honeysuckle, 6-15 parts of folium isatidis, 4-12 parts of fructus forsythia, 8-15 parts of isatis root, 5-12 parts of scutellaria baicalensis, 5-10 parts of coptis chinensis, 5-15 parts of mangnolia officinalis, 6-15 parts of hawthorn, 5-10 parts of malt, 5-15 parts of medicated leaven, 5-10 parts of fushen and 3-10 parts of rhizoma atractylodis. The compound traditional Chinese medicine is developed based on the holism concept of traditional Chinese veterinarians and syndrome differentiation treatment theory. The average weight of large broilers of 6 yearlings is 2468g, and the average feed conversion rate is 1.76, so the medicine is obvious in broiler growing promoting effect. The compound traditional Chinese medicine is prepared by completely adopting traditional Chinese medicine, and the broilers cannot have drug resistance in the growing and medicine taking process. No medicine residue is found in the boiler body. The medicine has the advantages of being simple in preparation method, convenient to use and the like.
The invention provides an artificial intelligence system for predicting prostate cancer risk based on various conventional physical examination indexes, which comprises: the system comprises a data acquisition module, a data cleaning module, a risk assessment module and a report generation and display module. The data acquisition module is used for directly calling the conventional physical examination index from the hospital information system. The data cleaning module is used for cleaning and preprocessing data. The risk assessment module is used for carrying out feature selection by using a feature selection algorithm of a random forest, and constructing a prediction model based on the selected features by using a prediction classification method of XGBoost. The report generation and display module is used for generating different reports according to different thresholds and displaying the evaluation results in a graph and table mode. The input of the prediction model is the conventional physical examination data of the patient, so that the cost can be saved, and the prediction model adopts the combination of the feature selection algorithm with the optimal effect and the classification method, so that the prediction accuracy of the prostate cancer risk is improved.
PROBLEM TO BE SOLVED: To obtain a health promoter useful for suppressing many kinds of fungi or viruses by combinedly using a phytoncide substance, etc., having pharmacological effect effective against many kinds of fungi and viruses with a water- soluble auxiliary capable of suppressing bleeding, etc. and having action capable of promoting absorption into an organism. SOLUTION: This health promoter is obtained by adding kojic acid as other germicide component to a phytoncide substance having a sterilizing component (e.g. hinokitiol) to afford a pharmacodynamic component and combinedly using the pharmacodynamic component and a water-soluble auxiliary having solvent action and action capable of promoting absorption into a body (e.g. propylene glycol) at (1-50wt.%) to (50-99wt.%) weight ratio. The health promoter is used for treating fish diseases caused in fishes.
Serious and fatal encephalopathy, including Wernicke's, has occurred in patients treated with INREBIC. Wernicke's encephalopathy is a neurologic emergency. Assess thiamine levels in all patients prior to starting INREBIC. Do not start INREBIC in patients with thiamine deficiency; replete thiamine prior to treatment initiation. While on treatment all patients should receive prophylaxis with daily oral thiamine and should have thiamine levels assessed as clinically indicated. If encephalopathy is suspected, immediately discontinue INREBIC and initiate parenteral thiamine. Monitor until symptoms resolve or improve and thiamine levels normalize [see Dosage and Administration (2.6), Warnings and Precautions (5.1) and Adverse Reactions (6.1)].
Function-oriented Neurodevelopmental Therapy will be applied to the subjects included in the study and randomly assigned to the study group in different positions such as supine, prone, sitting, standing for 6 weeks, 5 sessions per week, and the goal will be to achieve the task at different speeds. Spasticity, balance and gait exercises will be started at slow speeds, at muscle level, and in the following sessions, movement speed will be increased in relation to the patient's compliance, and global balance and gait exercises will be performed.
Unlike known methods of treatment, use of orgotein (I) is not painful and does not require long convalescene, and gives a more rapid clinical improvement. Method consists of the systemic administration by successive spaced doses of (I). For horses with bony exostosis, (I) is administered intramuscularly at 0.5-20 mg, pref. 2.5-5.0 mg/injection. For humans with hypertrophic arthritis (partic. osteoarthritis), (I) is given intramuscularly at 1-4 mg/injection for is not 2 weeks.
The identification of critical factors that can worsen the mechanisms contributing to the pathophysiology of Alzheimer disease is of paramount importance. Thyroid hormones (TH) fit this criterion. Epidemiological studies have identified an association between altered circulating TH levels and Alzheimer disease. The study of human and animal models indicates that TH can affect all the main cellular, molecular, and genetic mechanisms known as hallmarks of Alzheimer disease. This is true not only for the excessive production in the brain of protein aggregates leading to amyloid plaques and neurofibrillary tangles but also for the clearance of these molecules from the brain parenchyma via the blood-brain barrier and for the escalated process of neuroinflammation-and even for the effects of carrying Alzheimer-associated genetic variants. Suboptimal TH levels result in a greater accumulation of protein aggregates in the brain. The direct TH regulation of critical genes involved in amyloid beta production and clearance is remarkable, affecting the expression of multiple genes, including APP (related to amyloid beta production), APOE, LRP1, TREM2, AQP4, and ABCB1 (related to amyloid beta clearance). TH also affects microglia by increasing their migration and function and directly regulating the immunosuppressor gene CD73, impacting the immune response of these cells. Studies aiming to understand the mechanisms that could explain how changes in TH levels can contribute to the brain alterations seen in patients with Alzheimer disease are ongoing. These studies have potential implications for the management of patients with Alzheimer disease and ultimately can contribute to devising new interventions for these conditions.
Compounds of bismuth are caused to react, in the presence or not of an organic solvent such as ether, upon phosphatides such as lecithin; mixtures of bismuth compounds or mixtures of phosphatides may be used.  The products are suitable for the treatment of syphilis.  For injection they may be employed in conjunction with olive oil. According to examples, lecithin is caused to react with bismuth quinine iodide, and bismuth cholate.  The Specification as open to inspection under Sect. 91 (3) (a) describes also the replacement of the phosphatides by other substances possessing high dispersive qualities and forming with bismuth compounds other highly-dispersed lipoid-soluble compounds. Chloroform, carbon bisulphide, and benzene are also mentioned as solvents, whilst paraffin oils and oils containing phosphatides such as soya oil may replace the olive oil. Examples are also given in which lecithin is treated with the bismuth salt of 2-phenylquinoline-4-carboxylic-acid or of the trichlorbutyl ester of malonic acid.  This subject-matter does not appear in the Specification as accepted.ALSO:Compounds of bismuth are caused to react, in the presence or not of an organic solvent such as ether, upon phosphatides such as lecithin; mixtures of bismuth compounds or mixtures of phosphatides may be used.  The products are suitable for the treatment of syphilis.  According to examples lecithin is caused to react with bismuth quinine iodide, and bismuth cholate.  The Specification as open to inspection under Sect. 91 (3) (a) describes also the replacement of the phosphatides by other substances possessing high dispersive qualities and forming with bismuth compounds other highly-dispersed liquid-soluble compounds. Chloroform, carbon bisulphide, and benzene are mentioned as solvents. Examples are also given in which lecithin is treated with the bismuth salt of 2-phenylquinoline-4-carboxylic acid or of the trichlorbutyl ester of malonic acid.  This subject-matter does not appear in the Specification as accepted.